Neurocrine Biosciences Launches Phase 1 Trial for Novel Obesity Drug Targeting Muscle Preservation
Event summary
- Neurocrine Biosciences initiated a Phase 1 clinical trial for NBIP-'2118, a first-in-class CRF2 receptor agonist for obesity treatment.
- The study will evaluate safety and tolerability in healthy-weight, overweight, and obese adults, with initial data expected in 2027.
- NBIP-'2118 is designed for once-weekly subcutaneous administration and aims to reduce fat while preserving lean mass.
- Neurocrine's obesity pipeline includes NBIP-'1968 (triple agonist) and a single-molecule incretin-CRF2 conjugate.
- The company also develops a long-acting triple-agonist with extended half-life for potential once-monthly dosing.
The big picture
Neurocrine Biosciences is expanding its obesity pipeline with a novel mechanism targeting CRF2 receptors, aiming to address limitations of current therapies such as muscle loss. The company's integrated strategy includes multiple preclinical programs, positioning it to compete in the growing obesity treatment market. Neurocrine's expertise in neuroscience and endocrine disorders supports its ambition to develop differentiated therapies for this chronic disease.
What we're watching
- Clinical Efficacy
- Whether NBIP-'2118 can demonstrate superior muscle preservation compared to existing obesity therapies.
- Combination Strategy
- The pace at which Neurocrine advances its combination therapies, particularly NBIP-'2118 with NBIP-'1968.
- Market Differentiation
- How Neurocrine positions NBIP-'2118 in a competitive obesity treatment landscape dominated by incretin-based therapies.
Related topics